Transcranial Focused Ultrasound Neuromodulation for Post-Stroke Motor Dysfunction
Transcranial Focused Ultrasound Neuromodulation in Post-Stroke Motor Dysfunction
This study aims to evaluate how transcranial focused ultrasound (tFUS) technology can promote neural network remodeling and functional recovery after stroke. By integrating signals from electroencephalography (EEG) and magnetic resonance imaging (MRI), the study will investigate how activating or inhibiting specific brain regions affects motor and cognitive recovery. The goal is to improve patients' motor and cognitive functions, reduce long-term disability, and enhance quality of life. The study also seeks to optimize stimulation parameters to maximize rehabilitation outcomes and explore the mechanisms underlying neuroprotection and functional reconstruction after stroke.
This is a case-control study involving a total of 60 participants. Participants will be ischemic stroke survivors aged 18-75 years, with first-ever stroke onset between 21 days and 6 months, stable vital signs, no consciousness disorders, and the ability to provide informed consent and cooperate with assessments. Eligible participants must have unilateral limb motor impairment, with an upper extremity modified Ashworth score ≤3, Brunnstrom stage II-V, and an upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60.
Participants will be assigned to either a neuromodulation group (receiving multi-modal neuromodulation targeting specific brain regions) or a control group (receiving sham stimulation or conventional treatment). Primary outcome measures include changes in FMA-UE scores, neuroimaging data (CT/MRI), EEG measurements (resting-state and task-state spectral power, functional connectivity), and laboratory markers (complete blood count, CRP, IL-6, S100β, BDNF). Secondary outcome measures include Brunnstrom stage, Ashworth grade, muscle strength, and patient comfort ratings. Safety will be monitored through blood routine tests, blood biochemistry, and coagulation function.
Statistical analysis will compare key indicator changes between the neuromodulation and control groups before and after intervention. Independent t-tests (for two groups) or ANOVA (for multiple groups) will be used to assess between-group differences, with non-parametric tests applied for data not following a normal distribution.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Xiao Zhang, Professor
- Numéro de téléphone: +86 18612228766
- E-mail: zhangxiao@hit.edu.cn
Lieux d'étude
-
-
Heilongjiang
-
Harbin, Heilongjiang, Chine, 150001
- Harbin Institute of Technology
-
Contact:
- Xiao Zhang, Professor
- Numéro de téléphone: +86 18612228766
- E-mail: zhangxiao@hit.edu.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- (1) Patients with a confirmed imaging diagnosis of first-ever ischemic stroke; (2) Unilateral limb motor involvement; (3) Modified Ashworth Scale (MAS) grade ≤3 for the upper extremity, Brunnstrom stage II-V, and upper extremity Fugl-Meyer Assessment (FMA-UE) score between 15 and 60 (inclusive); (4) Age 18-75 years, onset within 21 days to 6 months, in the subacute or recovery phase; (5) Stable vital signs, no consciousness impairment, informed consent provided, ability to cooperate with clinical assessments, and approval obtained from the institutional ethics committee.
Exclusion Criteria:
- (1) Contraindications to MRI; (2) Infarction involving the thalamus; (3) Risk of intracranial hemorrhage; (4) Presence of intracranial metallic foreign bodies, cardiac pacemakers, or cochlear implants; (5) Unstable medical condition, severe cognitive impairment or psychiatric disorders rendering the patient unable to comprehend the study or cooperate with assessments; (6) Conditions affecting limb motor function, including fractures, joint contractures, or severe limb spasticity; (7) Current use of medications that alter cortical excitability.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Neuromodulation Group
Multimodal neuromodulation targeting specific neural regions in addition to conventional therapy.
|
The transcranial focused ultrasound stimulation device employed in this study is the NeuroFUS DPX-500, equipped with a 4-element transducer array and the BrainSight neuronavigation system.
Individualized modeling and target segmentation are performed using high-resolution structural MRI and CT images acquired at baseline.
Target planning and neuronavigation are conducted based on intracranial acoustic field simulation.
The total stimulation duration is 12 minutes, comprising 480 pulse trains with 0.5 seconds on and 1 second off, yielding a duty cycle of 20%.
|
|
Comparateur factice: Control Group
Sham stimulation in addition to conventional therapy.
|
The control group receives sham stimulation during the neuromodulation phase.
All procedural steps are identical to those of the experimental group, including neuronavigation positioning, application of coupling gel, and all other preparatory procedures; however, ultrasound stimulation is not activated.
Participants in the control group wear bone-conduction headphones to simulate and counteract acoustic confounding.
Group allocation information is blinded to participants.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Upper extremity Fugl-Meyer Assessment (UE-FMA) motor score
Délai: Baseline (Day 1), Day 7 ( after the 5-day intervention), and Day 21 (2-week follow-up)
|
Upper extremity motor function assessed by the Fugl-Meyer Assessment (motor subscale).
Total score ranges from 0 to 66, with higher scores indicating better motor function.
|
Baseline (Day 1), Day 7 ( after the 5-day intervention), and Day 21 (2-week follow-up)
|
|
Resting-state EEG spectral power
Délai: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Resting-state EEG spectral power in the delta, theta, alpha, beta, and gamma frequency bands.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
|
Task-state EEG spectral power
Délai: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Task-state EEG spectral power in the delta, theta, alpha, beta, and gamma frequency bands.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
|
Resting-state fMRI fractional ALFF (fALFF)
Délai: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
fALFF derived from resting-state functional MRI, the ratio of low-frequency power to whole-frequency power.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
|
Resting-state fMRI regional homogeneity (ReHo)
Délai: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
ReHo (Kendall's coefficient of concordance) from resting-state functional MRI, reflecting local synchronization of neuronal activity.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
|
Resting-state fMRI functional connectivity (FC)
Délai: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Functional connectivity between regions of interest derived from resting-state functional MRI (Fisher z-transformed correlation coefficients).
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Brunnstrom recovery stage of the affected upper limb
Délai: Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
|
Motor recovery staged using the Brunnstrom approach, an ordinal scale from Stage 1 (flaccid, no movement) to Stage 6 (near-normal coordination), with higher stages indicating better motor recovery.
|
Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
|
|
Modified Ashworth Scale (MAS) grade of the affected upper limb
Délai: Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
|
Muscle spasticity graded with the Modified Ashworth Scale, an ordinal scale with 6 levels (0, 1, 1+, 2, 3, 4); higher grades indicate greater spasticity (a worse outcome).
|
Baseline (Day 1), Day 7 (after the 5-day intervention), and Day 21 (2-week follow-up)
|
|
Fractional anisotropy (FA) on diffusion tensor imaging (DTI)
Délai: Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
White-matter fractional anisotropy measured by diffusion tensor imaging.
Dimensionless (0-1), with higher values indicating greater directional coherence of water diffusion.
|
Baseline (Day 1) and Day 7 (after the 5-day intervention)
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LSKY 2026-040-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .